Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The Healthcare Business posted lower sales and income as domestic sales remained sluggish despite growth in export sales through cross-border e-commerce. In the Plastic Products Business, raw material prices remained elevated due to supply restrictions on naphtha, but proactive price revisions proved effective, resulting in higher sales and a recovery in profitability. Ordinary income increased due to the recognition of ¥108 million in foreign exchange gains. The Other Business posted lower sales following the completion of its withdrawal from the nursing care business.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥1,617 million (YoY -9.6%) |
| Operating profit | ¥149 million (YoY -37.5%) |
| Ordinary income | ¥219 million (YoY +466.7%) |
| Profit attributable to owners of the parent | ¥134 million |
| Net income per share | ¥12.38 |
| Equity ratio | End of the current fiscal period 60.5 / End of previous period 60.6 |
| Total assets | ¥19,820 million |
| Net assets | ¥12,284 million |
| Full-year earnings forecast | Net Sales ¥6,400 million (YoY +8.3%) / Operating profit ¥380 million (YoY +112.8%) / Ordinary income ¥250 million (YoY -57.3%) / Net income ¥60 million (YoY -78.7%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥10 → ¥10（0.0%） |
| Segment revenue | Healthcare Business ¥1,221,881 thousand (YoY -15.8%), Plastic Products Business ¥394,240 thousand (YoY +29.2%), Other ¥1,569 thousand (YoY -95.4%) |
| Segment profit | Healthcare Business ¥281,578 thousand (YoY -24.5%), Plastic Products Business ¥41,867 thousand, Other ¥-870 thousand |
| Depreciation and amortization | ¥204,467 thousand |
| Impairment loss | Not applicable. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥364 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New — companies / Excluded — companies / Company name Not disclosed / Notes udon udon TOKYO株式会社 was excluded from the scope of equity-method affiliates. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 10,937,449 |
| Treasury Shares at Period-End | 81,502 |
| Factors Behind Changes in Business Performance | The Healthcare Business posted lower sales and income as domestic sales remained sluggish despite growth in export sales through cross-border e-commerce. In the Plastic Products Business, raw material prices remained elevated due to supply restrictions on naphtha, but proactive price revisions proved effective, resulting in higher sales and a recovery in profitability. Ordinary income increased due to the recognition of ¥108 million in foreign exchange gains. The Other Business posted lower sales following the completion of its withdrawal from the nursing care business. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Healthcare Business, domestic sales remained sluggish, and the company struggled to respond to changes in purchasing trends resulting from the prolonged increase in prices. In the Plastic Products Business, raw material prices remained elevated due to supply restrictions on naphtha, but proactive price revisions proved effective. The company also recognized ¥108 million in foreign exchange gains.